4//SEC Filing
SCHEINBERG DAVID A 4
Accession 0001209191-17-067659
CIK 0001390478other
Filed
Dec 28, 7:00 PM ET
Accepted
Dec 29, 5:11 PM ET
Size
5.6 KB
Accession
0001209191-17-067659
Insider Transaction Report
Form 4
SCHEINBERG DAVID A
Director
Transactions
- Award
Common Stock
2017-12-29+9,107→ 9,107 total
Footnotes (2)
- [F1]In connection with the merger of SELLAS Life Sciences Group, Ltd ("SELLAS") and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"), outstanding restricted stock units ("RSUs") to be settled in SELLAS common shares were assumed by the Issuer and will be settled in shares of the Issuer's common stock based on the following exchange ratio: 43.9972 shares of the Issuer's common stock for each common share of SELLAS.
- [F2]Represents shares issuable upon vesting of RSUs. 100% of the shares subject to the RSUs will vest on February 27, 2018.
Documents
Issuer
SELLAS Life Sciences Group, Inc.
CIK 0001390478
Entity typeother
Related Parties
1- filerCIK 0001250316
Filing Metadata
- Form type
- 4
- Filed
- Dec 28, 7:00 PM ET
- Accepted
- Dec 29, 5:11 PM ET
- Size
- 5.6 KB